Skip to main content
. 2020 Nov 12;10:594125. doi: 10.3389/fonc.2020.594125

Figure 1.

Figure 1

Kaplan–Meier survival curves. (A) PFS of 21 evaluable patients. (B) OS of the whole cohort. (C) PFS in patients with or without liver metastasis (p > 0.05). (D) PFS in patients with or without previous exposure to regorafenib (rego) (p > 0.05). Data cut-off date for survival results was July 15, 2020.